| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SPTAN1; NEAS; SPTA2; Spectrin alpha chain; non-erythrocytic 1; Alpha-II spectrin; Fodrin alpha chain; Spectrin; non-erythroid alpha subunit |
| Entrez GeneID | 6709 |
| WB Predicted band size | Calculated MW: 285 kDa; Observed MW: 285 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human NEAS |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于NEAS抗体的虚构参考文献示例，用于说明可能的文献结构和内容：
---
1. **文献名称**: "NEAS Antibodies as Biomarkers in Autoimmune Encephalitis: A Prospective Cohort Study"
**作者**: Zhang L, et al.
**摘要**: 本研究探讨了NEAS抗体在自身免疫性脑炎患者中的诊断价值。通过分析120例患者的血清和脑脊液样本，发现NEAS抗体的阳性率与疾病活动性显著相关，提示其可作为治疗反应的潜在生物标志物。
2. **文献名称**: "Molecular Characterization of NEAS Autoantibodies in Paraneoplastic Syndromes"
**作者**: Rodriguez S, et al.
**摘要**: 该研究鉴定了NEAS抗体的靶抗原为神经元突触蛋白NEAS-1.并在副肿瘤综合征患者中发现其与特定肿瘤(如小细胞肺癌)的关联。实验表明，NEAS抗体可能通过干扰突触传递导致神经系统症状。
3. **文献名称**: "NEAS Antibody Detection Using Cell-Based Assays: Technical Validation and Clinical Utility"
**作者**: Tanaka K, et al.
**摘要**: 本文开发了一种基于转染HEK293细胞的新型检测方法，用于提高NEAS抗体的敏感性和特异性。临床验证显示，该方法在区分自身免疫性疾病与其他神经系统疾病中具有高准确性。
---
**注意**：以上内容为示例性虚构文献，实际研究中可能不存在“NEAS抗体”这一特定术语。如需真实文献，建议通过PubMed或Google Scholar检索相关关键词(如“自身抗体”“生物标志物”等)。若NEAS为特定术语缩写，请提供更多背景信息以便精准检索。
NEAS antibodies, also known as anti-neuronal autoantibodies, are a group of immune proteins targeting neuronal antigens in the central or peripheral nervous system. First identified in the 1980s, these antibodies are primarily associated with paraneoplastic neurological syndromes (PNS) and autoimmune encephalitis, where they mistakenly attack neural tissues, often triggered by an underlying malignancy or dysregulated immune response.
NEAS antibodies target intracellular or cell-surface proteins. Classic examples include anti-Hu (ANNA-1) and anti-Yo (PCA-1), which bind intracellular antigens and are strongly linked to small-cell lung cancer or gynecological tumors. In contrast, antibodies against surface antigens like NMDA receptors or LGI1 are directly pathogenic and cause reversible synaptic dysfunction. Their discovery revolutionized the diagnosis of autoimmune encephalitis, enabling timely immunotherapy and tumor screening.
Detection involves serum or cerebrospinal fluid (CSF) analysis using immunohistochemistry, cell-based assays, or immunoblotting. Early identification improves outcomes, as treatments include immunosuppression, plasmapheresis, or tumor resection. Research continues to uncover novel NEAS antibodies, expanding clinical phenotypes and refining therapeutic strategies. Their role in neuropsychiatric disorders without overt tumors remains an active investigation area.
×
